Glenmark to launch generic sodium bicarbonate injection in November 2025

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced its plan to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial in November 2025. This new product is bioequivalent and therapeutically equivalent to Abbott Laboratories Pharmaceutical Products Division's reference listed drug (NDA - 019443).

The 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) market achieved annual sales of approximately $63.8 million for the 12-month period ending August 2025, according to IQVIA sales data. Marc Kikuchi, president & business head, North America, stated that this launch reinforces Glenmark's commitment to providing quality and affordable alternatives to patients.

Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company with a focus on respiratory, dermatology, and oncology. The company operates in over 80 countries and has 11 manufacturing facilities.